These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

463 related items for PubMed ID: 29733441

  • 1. The Effect of Lesinurad in Combination With Allopurinol on Serum Uric Acid Levels in Patients With Gout.
    Baumgartner S, Yeh LT, Shen Z, Kerr B, Manhard K, Quart B.
    J Clin Pharmacol; 2018 Sep; 58(9):1164-1170. PubMed ID: 29733441
    [Abstract] [Full Text] [Related]

  • 2. Lesinurad in combination with allopurinol: a randomised, double-blind, placebo-controlled study in patients with gout with inadequate response to standard of care (the multinational CLEAR 2 study).
    Bardin T, Keenan RT, Khanna PP, Kopicko J, Fung M, Bhakta N, Adler S, Storgard C, Baumgartner S, So A.
    Ann Rheum Dis; 2017 May; 76(5):811-820. PubMed ID: 27821644
    [Abstract] [Full Text] [Related]

  • 3. Lesinurad Combined With Allopurinol: A Randomized, Double-Blind, Placebo-Controlled Study in Gout Patients With an Inadequate Response to Standard-of-Care Allopurinol (a US-Based Study).
    Saag KG, Fitz-Patrick D, Kopicko J, Fung M, Bhakta N, Adler S, Storgard C, Baumgartner S, Becker MA.
    Arthritis Rheumatol; 2017 Jan; 69(1):203-212. PubMed ID: 27564409
    [Abstract] [Full Text] [Related]

  • 4. Pharmacodynamic, pharmacokinetic and tolerability evaluation of concomitant administration of lesinurad and febuxostat in gout patients with hyperuricaemia.
    Fleischmann R, Kerr B, Yeh LT, Suster M, Shen Z, Polvent E, Hingorani V, Quart B, Manhard K, Miner JN, Baumgartner S, RDEA594-111 Study Group.
    Rheumatology (Oxford); 2014 Dec; 53(12):2167-74. PubMed ID: 24509406
    [Abstract] [Full Text] [Related]

  • 5. Lesinurad: A Review in Hyperuricaemia of Gout.
    Deeks ED.
    Drugs Aging; 2017 May; 34(5):401-410. PubMed ID: 28425024
    [Abstract] [Full Text] [Related]

  • 6. Lesinurad in combination with allopurinol: results of a phase 2, randomised, double-blind study in patients with gout with an inadequate response to allopurinol.
    Perez-Ruiz F, Sundy JS, Miner JN, Cravets M, Storgard C, RDEA594-203 Study Group.
    Ann Rheum Dis; 2016 Jun; 75(6):1074-80. PubMed ID: 26742777
    [Abstract] [Full Text] [Related]

  • 7. Lesinurad, a Selective Uric Acid Reabsorption Inhibitor, in Combination With Febuxostat in Patients With Tophaceous Gout: Findings of a Phase III Clinical Trial.
    Dalbeth N, Jones G, Terkeltaub R, Khanna D, Kopicko J, Bhakta N, Adler S, Fung M, Storgard C, Baumgartner S, Perez-Ruiz F.
    Arthritis Rheumatol; 2017 Sep; 69(9):1903-1913. PubMed ID: 28597604
    [Abstract] [Full Text] [Related]

  • 8. Impact of Lesinurad and allopurinol on experimental Hyperuricemia in mice: biochemical, molecular and Immunohistochemical study.
    Alghamdi YS, Soliman MM, Nassan MA.
    BMC Pharmacol Toxicol; 2020 Feb 10; 21(1):10. PubMed ID: 32041665
    [Abstract] [Full Text] [Related]

  • 9. Comparison of efficacy and safety of urate-lowering therapies for hyperuricemic patients with gout: a meta-analysis of randomized, controlled trials.
    Fan M, Liu J, Zhao B, Wu X, Li X, Gu J, Schlesinger N.
    Clin Rheumatol; 2021 Feb 10; 40(2):683-692. PubMed ID: 32654080
    [Abstract] [Full Text] [Related]

  • 10. Cost-Effectiveness Analysis of Lesinurad/Allopurinol Versus Febuxostat for the Management of Gout/Hyperuricemia in Italy.
    Ruggeri M, Basile M, Drago C, Rolli FR, Cicchetti A.
    Pharmacoeconomics; 2018 May 10; 36(5):625-636. PubMed ID: 29557073
    [Abstract] [Full Text] [Related]

  • 11. Efficacy and Safety of Lesinurad in Patients with Hyperuricemia Associated with Gout: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
    Wu JY, Chang YT, Lin YC, Lee CH, Loh EW, Wu MY, Chang YS, Tam KW.
    Pharmacotherapy; 2018 Nov 10; 38(11):1106-1119. PubMed ID: 30246299
    [Abstract] [Full Text] [Related]

  • 12. New urate-lowing therapies.
    Abhishek A.
    Curr Opin Rheumatol; 2018 Mar 10; 30(2):177-182. PubMed ID: 29251661
    [Abstract] [Full Text] [Related]

  • 13. Lesinurad/Allopurinol (Duzallo) for Gout-Associated Hyperuricemia.
    JAMA; 2018 Jan 09; 319(2):188-189. PubMed ID: 29318274
    [No Abstract] [Full Text] [Related]

  • 14. Interventions for tophi in gout.
    Sriranganathan MK, Vinik O, Pardo Pardo J, Bombardier C, Edwards CJ.
    Cochrane Database Syst Rev; 2021 Aug 11; 8(8):CD010069. PubMed ID: 34379791
    [Abstract] [Full Text] [Related]

  • 15. Second-line treatment with lesinurad and allopurinol versus febuxostat for management of hyperuricemia: a cost-effectiveness analysis for Spanish patients.
    Presa M, Pérez-Ruiz F, Oyagüez I.
    Clin Rheumatol; 2019 Dec 11; 38(12):3521-3528. PubMed ID: 31420811
    [Abstract] [Full Text] [Related]

  • 16. Lesinurad for the treatment of hyperuricaemia in people with gout.
    Robinson PC, Dalbeth N.
    Expert Opin Pharmacother; 2017 Dec 11; 18(17):1875-1881. PubMed ID: 29103339
    [Abstract] [Full Text] [Related]

  • 17. Impact of Non-Adherence and Flare Resolution on the Cost-Effectiveness of Treatments for Gout: Application of a Linked Pharmacometric/Pharmacoeconomic Model.
    Hill-McManus D, Marshall S, Soto E, Lane S, Hughes D.
    Value Health; 2018 Dec 11; 21(12):1373-1381. PubMed ID: 30502780
    [Abstract] [Full Text] [Related]

  • 18. Lesinurad/allopurinol (Duzallo) for gout-associated hyperuricemia.
    Med Lett Drugs Ther; 2017 Nov 06; 59(1533):182-183. PubMed ID: 29125593
    [No Abstract] [Full Text] [Related]

  • 19. Effects of renal function on pharmacokinetics and pharmacodynamics of lesinurad in adult volunteers.
    Gillen M, Valdez S, Zhou D, Kerr B, Lee CA, Shen Z.
    Drug Des Devel Ther; 2016 Nov 06; 10():3555-3562. PubMed ID: 27843295
    [Abstract] [Full Text] [Related]

  • 20. Lesinurad monotherapy in gout patients intolerant to a xanthine oxidase inhibitor: a 6 month phase 3 clinical trial and extension study.
    Tausche AK, Alten R, Dalbeth N, Kopicko J, Fung M, Adler S, Bhakta N, Storgard C, Baumgartner S, Saag K.
    Rheumatology (Oxford); 2017 Dec 01; 56(12):2170-2178. PubMed ID: 29029210
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.